These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 33707314)

  • 1. Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic.
    Donahue RN; Marté JL; Goswami M; Toney NJ; Tsai YT; Gulley JL; Schlom J
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: modes of immune activation and future challenges.
    Teijaro JR; Farber DL
    Nat Rev Immunol; 2021 Apr; 21(4):195-197. PubMed ID: 33674759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T Cell Memory: Understanding COVID-19.
    Jarjour NN; Masopust D; Jameson SC
    Immunity; 2021 Jan; 54(1):14-18. PubMed ID: 33406391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.
    Jordan SC
    Clin Exp Immunol; 2021 Jun; 204(3):310-320. PubMed ID: 33534923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome.
    Borges RC; Hohmann MS; Borghi SM
    Int Rev Immunol; 2021; 40(1-2):108-125. PubMed ID: 33191813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune profiling of COVID-19: preliminary findings and implications for the pandemic.
    Maecker HT
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covid-19 vaccines: delivering protective immunity.
    Sewell HF; Agius RM; Kendrick D; Stewart M
    BMJ; 2020 Dec; 371():m4838. PubMed ID: 33334862
    [No Abstract]   [Full Text] [Related]  

  • 8. T Cells: Warriors of SARS-CoV-2 Infection.
    de Candia P; Prattichizzo F; Garavelli S; Matarese G
    Trends Immunol; 2021 Jan; 42(1):18-30. PubMed ID: 33277181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination immunology in SARS-CoV-2].
    Helweg-Larsen J; Benfield T
    Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response.
    Loretelli C; Abdelsalam A; D'Addio F; Ben Nasr M; Assi E; Usuelli V; Maestroni A; Seelam AJ; Ippolito E; Di Maggio S; Loreggian L; Radovanovic D; Vanetti C; Yang J; El Essawy B; Rossi A; Pastore I; Montefusco L; Lunati ME; Bolla AM; Biasin M; Antinori S; Santus P; Riva A; Zuccotti GV; Galli M; Rusconi S; Fiorina P
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34784300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperinflammation and Immune Response Generation in COVID-19.
    Mishra KP; Singh AK; Singh SB
    Neuroimmunomodulation; 2020; 27(2):80-86. PubMed ID: 33341814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.
    Saadeldin MK; Abdel-Aziz AK; Abdellatif A
    Med Hypotheses; 2021 Jan; 146():110365. PubMed ID: 33221134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
    Abid MB
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes.
    Tang G; Huang M; Luo Y; Liu W; Lin Q; Mao L; Wu S; Xiong Z; Hou H; Sun Z; Wang F
    Front Immunol; 2021; 12():697622. PubMed ID: 34777333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
    Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
    Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
    [No Abstract]   [Full Text] [Related]  

  • 16. How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?
    Kumar V
    Int Rev Immunol; 2021; 40(1-2):72-107. PubMed ID: 33155525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.
    Boechat JL; Chora I; Morais A; Delgado L
    Pulmonology; 2021; 27(5):423-437. PubMed ID: 33867315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Adequate T and B Cell Responses in a SARS-CoV-2 Infected Patient After Immune Checkpoint Inhibition.
    de Joode K; Oostvogels AAM; GeurtsvanKessel CH; de Vries RD; Mathijssen RHJ; Debets R; van der Veldt AAM
    Front Immunol; 2021; 12():627186. PubMed ID: 33613575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
    Azar MM; Shin JJ; Kang I; Landry M
    Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing CD8
    Gujar S; Pol JG; Kim Y; Kroemer G
    Oncoimmunology; 2020 Jul; 9(1):1794424. PubMed ID: 32923158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.